Aprepitant interactions
Full monograph for AprepitantCheck it against another medicine
Medicines
466 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Acalabrutinib | Major | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of acalabrutinib, which is primarily metabolized… | 2 sources — open the full entry |
| Avanafil | Major | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of avanafil, which is primarily metabolized by the isoenzyme. | 6 sources — open the full entry |
| Brexpiprazole | Major | Metabolism | Coadministration with inhibitors of CYP450 3A4 and/or 2D6 may significantly increase the plasma concentrations of brexpiprazole, which is metabolized by these… | 5 sources — open the full entry |
| Brigatinib | Major | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of brigatinib, which is partially metabolized by… | 4 sources — open the full entry |
| Bromocriptine Mesylate | Major | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of bromocriptine. Orally administered… | 7 sources — open the full entry |
| Cilostazol | Major | Metabolism | Coadministration with inhibitors of CYP450 3A4 and/or 2C19 may increase the plasma concentrations of cilostazol and or its pharmacologically active… | 12 sources — open the full entry |
| Colchicine | Major | Metabolism | Coadministration with inhibitors of CYP450 3A4 may significantly increase the serum concentrations of colchicine, which is primarily metabolized by the… | 36 sources — open the full entry |
| Deflazacort | Major | Metabolism | Coadministration with potent or moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of 21-desdeflazacort, the active… | 3 sources — open the full entry |
| Elacestrant | Major | Metabolism | Coadministration with potent or moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of elacestrant, which is primarily… | 1 sources — open the full entry |
| Eplerenone | Major | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of eplerenone, which is primarily metabolized by the isoenzyme. | 1 sources — open the full entry |
| Everolimus | Major | Absorption · Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 and P-glycoprotein may significantly increase the plasma concentrations of everolimus following oral… | 2 sources — open the full entry |
| Fentanyl Citrate | Major | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of fentanyl, which is primarily metabolized by the isoenzyme. Increased… | 12 sources — open the full entry |
| Finerenone | Major | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of finerenone, which is primarily metabolized by… | 3 sources — open the full entry |
| Flibanserin | Major | Metabolism | Coadministration with moderate and potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of flibanserin, which is primarily… | 2 sources — open the full entry |
| Ibrutinib | Major | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ibrutinib, which is primarily metabolized by… | 6 sources — open the full entry |
| Ivabradine | Major | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ivabradine, which is primarily metabolized by… | 9 sources — open the full entry |
| Ivosidenib | Major | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ivosidenib, which is primarily metabolized by… | 5 sources — open the full entry |
| Lurasidone Hydrochloride | Major | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of lurasidone and its active metabolite, both of… | 7 sources — open the full entry |
| Lurbinectedin | Major | Metabolism | Coadministration with a moderate CYP450 3A4 inhibitor is predicted to increase lurbinectedin systemic exposure, which may increase the incidence and severity… | 2 sources — open the full entry |
| Mavacamten | Major | Metabolism | Coadministration with inhibitors of CYP450 2C19 or CYP450 3A4 may increase the plasma concentrations of mavacamten. Because mavacamten reduces systolic… | 1 sources — open the full entry |
| Neratinib Maleate | Major | Metabolism | Coadministration with potent or moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of neratinib, which is primarily… | 7 sources — open the full entry |
| Olaparib | Major | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of olaparib, which is primarily metabolized by the… | 6 sources — open the full entry |
| Ranolazine | Major | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ranolazine, which is primarily metabolized by the isoenzyme. Because… | 4 sources — open the full entry |
| Selpercatinib | Major | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of selpercatinib, which is primarily metabolized… | 34 sources — open the full entry |
| Suvorexant | Major | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of suvorexant, which is primarily metabolized by… | 2 sources — open the full entry |
| Venetoclax | Major | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of venetoclax, which is a substrate of the isoenzyme. | 4 sources — open the full entry |
| Abametapir | Moderate | Metabolism | Based on in vitro inhibition data, a single topical application of abametapir lotion may increase plasma concentrations of drugs that are substrates of CYP450… | 1 sources — open the full entry |
| Abemaciclib | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of abemaciclib and its pharmacologically active metabolites, all of which… | 2 sources — open the full entry |
| Acyclovir + Hydrocortisone | Moderate | Metabolism · Unknown | Coadministration with aprepitant or its prodrug, fosaprepitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4…2 documented mechanisms | 2 sources — open the full entry |
| Albendazole | Moderate | Metabolism | Coadministration with aprepitant or its prodrug, fosaprepitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4… | 2 sources — open the full entry |
| Alfuzosin Hydrochloride | Moderate | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of alfuzosin, which is primarily metabolized by the isoenzyme… | 2 sources — open the full entry |
| Almotriptan | Moderate | Metabolism | Coadministration with aprepitant or its prodrug, fosaprepitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4… | 2 sources — open the full entry |
| Alprazolam | Moderate | Metabolism | Coadministration with aprepitant or its prodrug, fosaprepitant, may increase the plasma concentrations of benzodiazepines that are metabolized by CYP450 3A4… | 4 sources — open the full entry |
| Amiodarone Hydrochloride | Moderate | Metabolism | Coadministration with aprepitant or its prodrug, fosaprepitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4… | 2 sources — open the full entry |
| Amlodipine Besilate | Moderate | Metabolism | Coadministration with CYP450 3A4 inhibitors may increase the plasma concentrations of amlodipine, which is a substrate of the isoenzyme. | 5 sources — open the full entry |
| Amlodipine Besilate + Atenolol | Moderate | Metabolism · Unknown | Coadministration with CYP450 3A4 inhibitors may increase the plasma concentrations of amlodipine, which is a substrate of the isoenzyme.2 documented mechanisms | 5 sources — open the full entry |
| Amlodipine Besilate + Atorvastatin | Moderate | Metabolism | Coadministration with CYP450 3A4 inhibitors may increase the plasma concentrations of amlodipine, which is a substrate of the isoenzyme.2 documented mechanisms | 76 sources — open the full entry |
| Amlodipine Besilate + Benazepril Hydrochloride | Moderate | Metabolism | Coadministration with CYP450 3A4 inhibitors may increase the plasma concentrations of amlodipine, which is a substrate of the isoenzyme. | 5 sources — open the full entry |
| Amlodipine Besilate + Olmesartan Medoxomil | Moderate | Metabolism | Coadministration with CYP450 3A4 inhibitors may increase the plasma concentrations of amlodipine, which is a substrate of the isoenzyme. | 5 sources — open the full entry |
| Amlodipine Besilate + Telmisartan | Moderate | Metabolism · Unknown | Coadministration with CYP450 3A4 inhibitors may increase the plasma concentrations of amlodipine, which is a substrate of the isoenzyme.2 documented mechanisms | 5 sources — open the full entry |
| Amlodipine Besilate + Valsartan | Moderate | Metabolism · Unknown | Coadministration with CYP450 3A4 inhibitors may increase the plasma concentrations of amlodipine, which is a substrate of the isoenzyme.2 documented mechanisms | 5 sources — open the full entry |
| Apalutamide | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of aprepitant, which is primarily metabolized by the isoenzyme. | 2 sources — open the full entry |
| Apixaban | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein (P-gp) may increase the plasma concentrations of apixaban, which is a substrate of both… | 2 sources — open the full entry |
| Aripiprazole | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 and/or 2D6 may increase the plasma concentrations of aripiprazole, which is primarily metabolized by these… | 5 sources — open the full entry |
| Asciminib | Moderate | Metabolism | Coadministration with asciminib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme. The mechanism is… | 1 sources — open the full entry |
| Atorvastatin + Ezetimibe | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of HMG-CoA reductase inhibitors (i.e., statins) that are metabolized by… | 71 sources — open the full entry |
| Atorvastatin Calcium | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of HMG-CoA reductase inhibitors (i.e., statins) that are metabolized by… | 71 sources — open the full entry |
| Axitinib | Moderate | Metabolism | Coadministration with aprepitant or its prodrug, fosaprepitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4… | 2 sources — open the full entry |
| Azelastine Hydrochloride + Fluticasone Propionate | Moderate | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may increase the systemic exposure to fluticasone following intranasal administration or oral… | 7 sources — open the full entry |
| Beclomethasone Dipropionate + Chloramphenicol + Clotrimazole + Lidocaine | Moderate | Metabolism | Coadministration with aprepitant or its prodrug, fosaprepitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4…3 documented mechanisms | 4 sources — open the full entry |
Conditions
Conditions in which Aprepitant needs care, as documented in this source.
Liver Diseases
ModerateAprepitant is primarily metabolized by the liver. In studies of patients with mild to moderate hepatic impairment (Child-Pugh score 5 to 9), aprepitant was well tolerated and no clinically significant alterations in its pharmacokinetics were observed. Thus, no dosage adjustment of aprepitant is necessary in this patient population. However, there are no clinical or pharmacokinetic data in patients with severe hepatic impairment (Child-Pugh score > 9), and caution is advised if aprepitant is used in such patients.
1 source
- "Product Information. Emend (aprepitant)." Merck & Co., Inc (2003):
Therapeutic duplication
Drug classes that overlap with Aprepitant, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.
antiemetics
The recommended maximum number of medicines in the 'antiemetics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'antiemetics' category.
Example product in the source data (US market): Phenohytro
nk1 receptor antagonists
The recommended maximum number of medicines in the 'NK1 receptor antagonists' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'NK1 receptor antagonists' category.
Example product in the source data (US market): Netupitant/palonosetron
nk1 receptor antagonists
The recommended maximum number of medicines in the 'NK1 receptor antagonists' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'NK1 receptor antagonists' category.
Example product in the source data (US market): Fosnetupitant/palonosetron